The Technical Analyst
Kintara Therapeutics, [KTRA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Kintara Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals
15.08% $0.158
America/New_York / 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 8.74 mill |
| EPS: | -5.22 |
| P/E: | -0.0300 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 55.30 mill |
| Avg Daily Volume: | 14.07 mill |
| RATING 2024-04-25 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0300 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -0.0300 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.136 - 0.180 ( +/- 13.92%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-08-30 | Johnson Laura L. | Buy | 8 500 | Options (Right to Buy) |
| 2023-08-30 | Favorito Tamara A | Buy | 8 500 | Options (Right to Buy) |
| 2023-08-30 | Hoffman Robert E. | Buy | 23 142 | Options (Right to Buy) |
| 2023-08-30 | Toth Robert Joseph Jr | Buy | 8 500 | Options (Right to Buy) |
| 2023-08-30 | Brown Dennis M | Buy | 10 175 | Options (Right to Buy) |
| INSIDER POWER |
|---|
| 100.00 |
| Last 96 transactions |
| Buy: 12 848 509 | Sell: 15 566 |
Forecast:
16:00 - $0.160
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.160
Forecast 2: 16:00 - $0.160
Forecast 3: 16:00 - $0.160
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.158 (15.08% ) |
| Volume | 11.05 mill |
| Avg. Vol. | 14.07 mill |
| % of Avg. Vol | 78.55 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For KTRA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
KTRA
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
Last 10 Buy Signals
Latest Press Releases
2024-04-09 20:15:00 - Press Release
Stockholder Investigation: The M&a Class Action Firm Announces An Investigation Of Kintara Biopharma, Inc. - Ktra
New york , april 9, 2024 /prnewswire/ -- monteverde & associates pc (the "m&a class action firm"), has recovered money for shareholders and is recognized as a top 50 firm in the 2018-2022 iss securities class action services report. we are headquartered at the empire state building in new york city and is investigating kintara therapeutics, inc. (nasdaq: ktra), relating to its proposed merger with tuhura biosciences, inc. click here for more information: https://monteverdelaw.com/case/kintara-therapeutics-inc/.
2024-04-05 13:31:00 - Press Release
Kintara Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Merger Of Kintara Therapeutics, Inc. - Ktra
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed merger of kintara therapeutics, inc. (the “company”) (nasdaqcm: ktra) and tuhura biosciences, inc. ksf is seeking to determine whether the merger and the process that led to it are adequate, and whether the merger is fair to kintara shareholders. if you would like to discuss your legal rights regarding the proposed tr.
2024-04-03 13:43:00 - Press Release
Shareholder Alert: Ademi Llp Investigates Whether Kintara Therapeutics, Inc. Has Obtained A Fair Price In Its Transaction With Tuhura
Milwaukee , april 3, 2024 /prnewswire/ -- ademi llp is investigating kintara (nasdaq: ktra) for possible breaches of fiduciary duty and other violations of law in its transaction with tuhura. click here to learn how to join the https://www.ademilaw.com/case/kintara-therapeutics-inc or call guri ademi toll-free at 866-264-3995.
2024-04-03 09:28:00 - Press Release
Ktra Stock Alert: Halper Sadeh Llc Is Investigating Whether The Merger Of Kintara Therapeutics, Inc. Is Fair To Shareholders
New york--(business wire)--halper sadeh llc, an investor rights law firm, is investigating whether the merger of kintara therapeutics, inc. (nasdaq: ktra) and tuhura biosciences, inc. is fair to kintara shareholders. halper sadeh encourages kintara shareholders to click here to learn more about their legal rights and options or contact daniel sadeh or zachary halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. the investigation concerns whether kintara and its board vi.
2024-04-03 07:00:00 - Press Release
Kintara Therapeutics And Tuhura Biosciences Enter Into Definitive Merger Agreement
Tuhura is planning to advance a single phase 3 trial for ifx-2.0 personalized cancer vaccine as adjunctive therapy with keytruda® in first-line therapy for advanced merkel cell carcinoma in 2h 2024 under fda's accelerated approval pathway $31 million subscribed financing by tuhura in connection with the merger agreement expected to provide cash runway into late 2025 tuhura's first-in-class bifunctional antibody drug conjugates (adcs) represents potential upside partnering opportunities companies are to hold a joint conference call and webcast today, wednesday, april 3 at 8:30 am et san diego and tampa, fla. , april 3, 2024 /prnewswire/ -- kintara therapeutics, inc. (nasdaq: ktra) ("kintara"), a biopharmaceutical company investigating rem-001 in an nih-sponsored and funded open label study in cutaneous metastatic breast cancer, and tuhura biosciences, inc...
Latest News
2024-04-04 11:41:03 - Zacks Investment Research
Kintara (KTRA) Stock Soars on Merger Agreement With TuHURA
Kintara (KTRA) inks a definitive merger agreement with TuHURA for an all-stock transaction. It is expected to close in the third quarter of 2024.
2024-04-03 09:46:00 - InvestorPlace
Why Is Kintara Therapeutics (KTRA) Stock Up 103% Today?
Kintara Therapeutics (NASDAQ: KTRA ) stock is rocketing higher on Wednesday after the biopharmaceutical company announced plans to merge with TuHURA Biosciences . Kintara Therapeutics and TuHURA Biosciences will use an all-stock transaction to combine the two companies.
2024-03-31 06:26:00 - PennyStocks
Sizing Your Penny Stocks Position, 3 Tips
Sizing positions correctly is a cornerstone of successful investing, especially when dealing with penny stocks. The unique nature of penny stocks, with their potential for substantial gains, requires a nuanced approach to position sizing.
2023-12-01 10:47:45 - Benzinga
Top 5 Health Care Stocks That Could Blast Off In December - DBV Technologies (NASDAQ:DBVT), Cigna Group (NYSE:CI)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
2023-08-09 08:16:00 - PRNewsWire
Kintara Therapeutics to Present at the Emerging Growth Conference
SAN DIEGO , Aug. 9, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its President and CEO, Robert E. Hoffman will present in the Emerging Growth Conference on Wednesday, August 9, 2023 at 12:00 pm ET.
2023-06-30 12:12:09 - Zacks Investment Research
Kintara (KTRA) Rises 41% on $2M Grant for Breast Cancer Therapy
Kintara (KTRA) receives a $2 million grant from the National Institutes of Health to develop its breast cancer treatment candidate, REM-001. The stock surges 41%.
2023-03-10 08:30:00 - PRNewsWire
Kintara Therapeutics Scheduled to Present at Two Conferences the Week of March 13, 2023
-35th Annual ROTH Conference, March 12-14, 2023 – -4th Annual Glioblastoma Drug Development Summit, March 14-16, 2023- SAN DIEGO , March 10, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announces its participation in two upcoming conferences. 35th Annual ROTH Conference, March 12-14, 2023 – Dana Point, CA Mr.
2022-12-30 01:01:07 - MarketBeat
Is Kintara Therapeutics A Hidden Gem?
Kintara Therapeutics' earnings are in the red but impressive FDA approvals could satisfy an extreme upside potential to bring them solvent by next year.
2022-12-15 11:49:28 - Benzinga
Why Kintara Therapeutics Stock Is Seeing Blue Skies Thursday - Kintara Therapeutics (NASDAQ:KTRA)
Kintara Therapeutics Inc KTRA shares are trading higher by 24.09% to $9.94 Thursday morning after the company received FDA Orphan Drug Designation (ODD) for VAL-083.
2022-10-20 06:00:00 - PennyStocks
3 Strategies for Buying and Selling Penny Stocks Right Now
Can these penny stocks trading tips help your strategy? The post 3 Strategies for Buying and Selling Penny Stocks Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.